Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.68 USD | +2.34% | -5.18% | +16.16% |
May. 17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
May. 13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Financials (USD)
Sales 2024 * | 26.58M | Sales 2025 * | 78.61M | Capitalization | 181M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -4M | EV / Sales 2024 * | 6.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.3 x |
P/E ratio 2024 * |
-5.49
x | P/E ratio 2025 * |
-24.9
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.74% |
Latest transcript on Capricor Therapeutics, Inc.
1 day | +2.34% | ||
1 week | -5.18% | ||
1 month | +6.57% | ||
3 months | +24.42% | ||
6 months | +91.89% | ||
Current year | +16.16% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 5.68 | +2.34% | 385,871 |
24-05-30 | 5.55 | -0.89% | 492,672 |
24-05-29 | 5.6 | -8.20% | 608,214 |
24-05-28 | 6.1 | +1.84% | 503,765 |
24-05-24 | 5.99 | -1.32% | 235,713 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.16% | 181M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CAPR Stock